ArticleBMC cancer2025
Inequities by race and ethnicity in cancer treatment receipt among people living with HIV and cancer in the U.S. (2004-2020).
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cancer Screening Behaviors among People with HIV in the United States and the Role of Multi-Level Social and Economic Factors: A Systematic Review.Current epidemiology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivePeople with HIV (PWH) are less likely to receive cancer treatment compared to those without HIV. Social factors, such as cancer treatment facility type, which may impact cancer treatment receipt among PWH have not been quantitatively explored. Our objective was to characterize racial differences in social determinants of health (SDoH) that impact cancer treatment receipt among PWH and cancer in the US.
methodsWe used the National Cancer Database (2004-2020) and included adult (18-89 years) patients living with HIV identified using ICD9 and ICD10 codes. We included the 14 most common cancers that occur among PWH. Our main outcome was receipt of first-line cancer treatment, including systemic therapy, surgery, hormone therapy, and radiotherapy. Our main SDoH exposures included (1) area-level education or % of adults without a high school degree and (2) area-level income or median income quartiles within the patient's zip code. Healthcare access measures we evaluated included insurance status, distance to care, and cancer care facility type. We used hierarchical multivariable logistic regression models to estimate adjusted logistic ratios (aOR) with 95% confidence intervals (95% CI).
resultsWe included 31,549 patients with HIV and cancer, of which 16% did not receive treatment. Overall, 43% of patients were aged ≥ 60 years, 38% were NH-Black, 68% were male, and 39% of patients resided in the South. 47% of patients were diagnosed with stage I/II cancer, and the most common cancers included were lung (21%), diffuse large B-cell lymphoma (12%), colorectal (9%) cancers, and prostate(9%). Compared to those in the highest quartile (Q4), PWH in the lower quartiles of educational attainment were less likely to receive cancer treatment (Q1 vs. Q4: aOR:0.74; 95% CI:0.66-0.82). Residing in the lower quartiles of household income was also inversely associated with cancer treatment receipt (Q1 vs.Q4: aOR:0.73; 95% CI:0.65-0.82). These associations were consistent among NH-White and NH-Black PWH. PWH living within 2 miles of their cancer care facility (vs. >45 miles away) and those treated at community cancer programs (vs. an academic/research program) were less likely to receive cancer treatment.
conclusionArea-level markers of social disadvantage are associated with cancer treatment receipt among PWH, suggesting SDoH factors may impact inequities in cancer treatment by HIV status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.